Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target

benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mi

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Monday released interim results from the ongoing Phase 2 COURAGE trial.
The company is investigating novel combinations of Novo Nordisk A/S (NYSE:NVO) Wegovy (semaglutide) (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin)…

This story appeared on benzinga.com, 2025-06-02 15:59:16.
The Entire Business World on a Single Page. Free to Use →